Home/Filings/4/0001562180-24-001222
4//SEC Filing

Goldan Keith A. 4

Accession 0001562180-24-001222

CIK 0001395937other

Filed

Feb 8, 7:00 PM ET

Accepted

Feb 9, 4:05 PM ET

Size

13.1 KB

Accession

0001562180-24-001222

Insider Transaction Report

Form 4
Period: 2024-02-07
Goldan Keith A.
Chief Financial Officer
Transactions
  • Other

    Common Stock

    2024-01-31$17.42/sh+1,183$20,6084,673 total
  • Award

    Stock Options (Right to buy)

    2024-02-07$22.28/sh+70,000$1,559,60070,000 total
    Exercise: $22.28Exp: 2034-02-07Common Stock (70,000 underlying)
  • Other

    Common Stock

    2023-07-31$18.12/sh+862$15,6193,490 total
  • Award

    Common Stock

    2024-02-07+35,00039,673 total
  • Award

    Common Stock

    2024-02-07+11,70051,373 total
Footnotes (5)
  • [F1]The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 862 shares by the Reporting Person on 07/31/2023 pursuant to the Issuer's Employee Stock Purchase Plan.
  • [F2]The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,183 shares by the Reporting Person on 01/31/2024 pursuant to the Issuer's Employee Stock Purchase Plan.
  • [F3]Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.
  • [F4]Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.
  • [F5]1/48th of the shares subject to the option shall vest monthly over a four-year period.

Issuer

Syndax Pharmaceuticals Inc

CIK 0001395937

Entity typeother

Related Parties

1
  • filerCIK 0001495411

Filing Metadata

Form type
4
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 4:05 PM ET
Size
13.1 KB